AstraZeneca faces more Covid-19 vaccine questions after manufacturing error
AstraZeneca Plc and the University of Oxford face mounting questions
about their Covid-19 vaccine
trial results after acknowledging a manufacturing error.
While an announcement earlier this week by
Astra and Oxford showed their shot was 70 per cent effective on average in a
late-stage study, the scant details released by the UK partners have sparked
worries, with some expressing doubts about whether US regulators would clear
it.
Astra and Oxford had said their vaccine was
90 per cent effective when a half-dose was given before a full-dose booster.
Two full doses showed an efficacy of 62 per cent. But the head of the US
vaccine program known as Operation Warp Speed said the next day that the dose
showing the higher level of effectiveness was tested in a younger population. Read More
Comments
Post a Comment